Cancer research uk.org
Pseudomyxoma peritonei (PMP) is a rare type of cancer that affects the peritoneum. This cancer affects around two people in one million and is mostly found in patients between 40 and 60 years old.
PMP originates as an adenoma, a benign growth that can develop into an adenocarcinoma, its malignant form. The most frequent place for PMP to develop is the appendix, but PMP has also been found in the ovaries, bladder and intestines. Basically, PMP causes cells inside the appendix to produce excessive amounts of mucus, potentially causing the appendix to rupture, which allows cancerous cells to spread throughout the abdomen and onto the peritoneum.
There are three types of PMP:
Due to the very slow development of PMP, patients do not experience any symptoms until the disease is in its later stages. Symptoms may include:
The symptoms develop along the following stages:
There is no known cause for PMP.
Due to the rarity of PMP, the illness will most likely only be identified during its later stages by a specialist. Using ultrasounds, CT scans or MRI scans, PMP may be diagnosed, but keyhole surgery will, in most cases, provide a definitive diagnosis.
The choice of treatment for PMP patients is a combination of surgery and chemotherapy. The surgeon will try to remove as many tumorous growths from the abdomen as possible, following it up with chemotherapy in order to kill off any remaining cancer cells. The efficacy of the chemotherapy can be improved by heating the medication before administration. This procedure is known as HIPEC: hyperthermic intraperitoneal chemotherapy. If curing the patient is no longer a viable option, HIPEC can also be offered in a palliative setting.